Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 244

1.

Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.

Hernán MA, Brumback B, Robins JM.

Epidemiology. 2000 Sep;11(5):561-70.

PMID:
10955409
2.

Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures.

Hernán MA, Brumback BA, Robins JM.

Stat Med. 2002 Jun 30;21(12):1689-709.

PMID:
12111906
3.

Marginal structural models and causal inference in epidemiology.

Robins JM, Hernán MA, Brumback B.

Epidemiology. 2000 Sep;11(5):550-60.

PMID:
10955408
4.

Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models.

Cole SR, Hernán MA, Robins JM, Anastos K, Chmiel J, Detels R, Ervin C, Feldman J, Greenblatt R, Kingsley L, Lai S, Young M, Cohen M, Muñoz A.

Am J Epidemiol. 2003 Oct 1;158(7):687-94.

PMID:
14507605
5.

Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.

Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team.

Clin Infect Dis. 2008 Feb 15;46(4):507-15. doi: 10.1086/526524.

PMID:
18199042
6.

Zidovudine therapy, CD4+ and CD8+ counts are associated with a longer survival following AIDS onset.

Fiala M, Swartz J, Teklehaimanot S, Kermani V, Funnye AS, Sayre JW, Gornbein JA.

Lymphology. 1997 Sep;30(3):128-36.

PMID:
9313205
7.

Duration of the survival benefit of zidovudine therapy in HIV infection.

Moore RD, Keruly JC, Chaisson RE.

Arch Intern Med. 1996 May 27;156(10):1073-7.

PMID:
8638994
8.

A simple G-computation algorithm to quantify the causal effect of a secondary illness on the progression of a chronic disease.

van der Wal WM, Prins M, Lumbreras B, Geskus RB.

Stat Med. 2009 Aug 15;28(18):2325-37. doi: 10.1002/sim.3629.

PMID:
19499549
9.

Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.

Justice AC, Stein DS, Fusco GP, Sherrill BH, Fusco JS, Danehower SC, Becker SL, Hansen NI, Graham NM; CHORUS Program Team.

J Clin Epidemiol. 2004 Jan;57(1):89-97.

PMID:
15019015
10.
12.

Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment.

Mayeux R, Stern Y, Tang MX, Todak G, Marder K, Sano M, Richards M, Stein Z, Ehrhardt AA, Gorman JM.

Neurology. 1993 Jan;43(1):176-82.

PMID:
8093809
13.
14.

Effect modification by time-varying covariates.

Robins JM, Hernán MA, Rotnitzky A.

Am J Epidemiol. 2007 Nov 1;166(9):994-1002; discussion 1003-4. Epub 2007 Sep 17.

PMID:
17875581
15.

Residuals for proportional hazards models with interval-censored survival data.

Farrington CP.

Biometrics. 2000 Jun;56(2):473-82.

PMID:
10877306
17.

Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease.

Erbelding EJ, Chaisson RE, Gallant JE, Moore RD.

Antivir Ther. 1997 Apr;2(2):71-7.

PMID:
11322278
18.

Sensitivity analyses for unmeasured confounding assuming a marginal structural model for repeated measures.

Brumback BA, Hernán MA, Haneuse SJ, Robins JM.

Stat Med. 2004 Mar 15;23(5):749-67.

PMID:
14981673
19.

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.

Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.

J Infect Dis. 2004 Sep 15;190(6):1046-54. Epub 2004 Aug 17.

PMID:
15319852
20.

Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.

Jacobson LP, Li R, Phair J, Margolick JB, Rinaldo CR, Detels R, Muñoz A.

Am J Epidemiol. 2002 Apr 15;155(8):760-70.

PMID:
11943695

Supplemental Content

Support Center